JP2023546383A - アネキシンａ５組成物及び方法 - Google Patents

アネキシンａ５組成物及び方法 Download PDF

Info

Publication number
JP2023546383A
JP2023546383A JP2023521687A JP2023521687A JP2023546383A JP 2023546383 A JP2023546383 A JP 2023546383A JP 2023521687 A JP2023521687 A JP 2023521687A JP 2023521687 A JP2023521687 A JP 2023521687A JP 2023546383 A JP2023546383 A JP 2023546383A
Authority
JP
Japan
Prior art keywords
annexin
ace2
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521687A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546383A5 (enExample
Inventor
フェン、チンピン
ルー、シャンルー
ビー． スタソプロス、ピーター
バール、スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
London Health Sciences Centre Research Inc
Original Assignee
London Health Sciences Centre Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by London Health Sciences Centre Research Inc filed Critical London Health Sciences Centre Research Inc
Publication of JP2023546383A publication Critical patent/JP2023546383A/ja
Publication of JP2023546383A5 publication Critical patent/JP2023546383A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2023521687A 2020-10-09 2021-10-08 アネキシンａ５組成物及び方法 Pending JP2023546383A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089584P 2020-10-09 2020-10-09
US63/089,584 2020-10-09
PCT/CA2021/051422 WO2022073134A1 (en) 2020-10-09 2021-10-08 Annexin a5 compositions and methods

Publications (2)

Publication Number Publication Date
JP2023546383A true JP2023546383A (ja) 2023-11-02
JP2023546383A5 JP2023546383A5 (enExample) 2024-10-17

Family

ID=81126326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521687A Pending JP2023546383A (ja) 2020-10-09 2021-10-08 アネキシンａ５組成物及び方法

Country Status (4)

Country Link
US (1) US20230374091A1 (enExample)
JP (1) JP2023546383A (enExample)
CA (1) CA3198378A1 (enExample)
WO (1) WO2022073134A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025129329A1 (en) * 2023-12-23 2025-06-26 London Health Sciences Centre Research Inc. Methods for treatment of sepsis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505837A (ja) * 2008-10-17 2012-03-08 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
WO2022008654A1 (en) * 2020-07-09 2022-01-13 Exo Biologics Sa Process for the manufacturing of protein-associated extracellular vesicles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6843980B2 (en) * 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
DE10145254A1 (de) * 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
CA2481231A1 (en) * 2002-04-05 2003-10-23 University Of Utah Research Foundation Colon tumor specific binding peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505837A (ja) * 2008-10-17 2012-03-08 ロンドン ヘルス サイエンシーズ センター リサーチ インコーポレイテッド 炎症性障害の処置を処置するためのアネキシンおよびその使用
WO2022008654A1 (en) * 2020-07-09 2022-01-13 Exo Biologics Sa Process for the manufacturing of protein-associated extracellular vesicles

Also Published As

Publication number Publication date
US20230374091A1 (en) 2023-11-23
CA3198378A1 (en) 2022-04-14
WO2022073134A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
EP2858661B1 (en) Stabilized antiviral fusion helices
CN103052647A (zh) 抗病毒剂
EA017957B1 (ru) Композиции и способы, ингибирующие грипп
AU2021228098A1 (en) Soluble ACE2 and fusion protein, and applications thereof
PT1734987E (pt) Interfer†o-beta para terap—utica antivrica de doenãas respiratërias
US11364276B2 (en) Antiviral peptides for treatment of the middle east respiratory syndrome
CN116209672A (zh) Sars-cov-2抑制剂
US20230374091A1 (en) Annexin a5 compositions and methods
US11299518B2 (en) Fusion respiratory syncytial virus inhibitors and use thereof
CN117120459A (zh) 抗感染双环肽配体
CN113993884A (zh) 抑制呼吸道合胞病毒感染的生物及合成分子
US20090312252A1 (en) Antimicrobial Activity in Variants of Lacritin
US20240002437A1 (en) Compositions and methods of treating inflammatory lung diseases
WO2010043046A1 (en) Peptide inhibitors of type iii secretion
Wang et al. Characterisation and evaluation of antiviral recombinant peptides based on the heptad repeat regions of NDV and IBV fusion glycoproteins
WO2022221920A1 (en) Novel compositions and methods for treating coronavirus infections
CN113150107A (zh) 一种白细胞介素29突变体蛋白
WO2022036049A2 (en) Antiviral stapled peptides against sars-cov-2
US20250352614A1 (en) Peptide therapeutics for the treatment of cancer and uses thereof
JP7741108B2 (ja) インターロイキン２９変異体タンパク質
US11834480B2 (en) Protein inhibitors with reduced immunogenicity and resistance to degradation, and methods for their preparation and use
RU2837537C1 (ru) Растворимый апф2, его слитый белок и способы их применения
US12098175B2 (en) Peptide inhibitors targeting the CXCL12/HMGB1 interaction and uses thereof
JP2023547881A (ja) 重症急性呼吸器症候群コロナウイルス－２（ＳＡＲＳ－ＣｏＶ２）感染に対するＡＣＥ－２およびＳ１サブユニット模倣物としてのペプチドおよびそのコンジュゲート体
WO2024050300A2 (en) Synthetic surfactants for inhibiting coronavirus infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260724